Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H18N4OS |
| Molecular Weight | 374.459 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CNC2=C(SC3=CC=C4N=C(C=CC4=C23)C5=CN=C(C)C=C5)C(=O)N1
InChI
InChIKey=CMWRPDHVGMHLSZ-GFCCVEGCSA-N
InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1
| Molecular Formula | C21H18N4OS |
| Molecular Weight | 374.459 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20237073Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24601623 | http://google.com/patents/WO2015173788A1 | https://www.ncbi.nlm.nih.gov/pubmed/22746295
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20237073
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24601623 | http://google.com/patents/WO2015173788A1 | https://www.ncbi.nlm.nih.gov/pubmed/22746295
PF 3644022 is potent, ATP-competitive inhibitor of mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) (IC50 = 5.2 nM; Ki = 3 nM). Inhibits tumor necrosis factor α (TNFα) production in U937 monocytic cells and peripheral blood mononuclear cells (PBMCs) (IC50 = 160 nM). PF-3644022 is orally efficacious at inhibiting TNFalpha production in LPS-challenged rats and blocking paw swelling in the chronic SCW-arthritis model.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22746295 |
5.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20237073
Arthritis was induced in 125- to 140-g female Lewis rats (Harlan) by a single intraperitoneal injection of peptidoglycan–polysaccharide complexes from group A SCW purchased from Lee Laboratories (Grayson, GA). The disease course was biphasic with an acute inflammatory non-T cell-dependent phase on days 1 to 3 followed by a chronic T cell-ependent inflammatory-erosive arthritis developing over days 14 to 28. Animals developing the acute inflammatory phase were pooled into groups of seven to eight animals per group and dosed with PF-3644022 or methylcellulose-Tween 20 vehicle by oral gavage (1 ml) twice a day for days 10 to 21. Hind paw swelling volumes were measured on day 21 with a displacement plethysmometer
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20237073
PF-3644022 was added to human whole blood (HWB) ex vivo 1 h before stimulation with 100 ng/ml LPS at 37°C. TNFalpha was measured 4 h poststimulation by assaying plasma with a human TNFalpha MSD kit. TNFalpha, IL-1, IL-6, and IL-8 in plasma was also measured after 16-h LPS stimulation of HWB by using a four-plex human cytokine MSD plate
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 05:44:52 GMT 2025
by
admin
on
Wed Apr 02 05:44:52 GMT 2025
|
| Record UNII |
N4H5CH3E5S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1276121-88-0
Created by
admin on Wed Apr 02 05:44:52 GMT 2025 , Edited by admin on Wed Apr 02 05:44:52 GMT 2025
|
PRIMARY | |||
|
44631903
Created by
admin on Wed Apr 02 05:44:52 GMT 2025 , Edited by admin on Wed Apr 02 05:44:52 GMT 2025
|
PRIMARY | |||
|
N4H5CH3E5S
Created by
admin on Wed Apr 02 05:44:52 GMT 2025 , Edited by admin on Wed Apr 02 05:44:52 GMT 2025
|
PRIMARY | |||
|
DTXSID901352019
Created by
admin on Wed Apr 02 05:44:52 GMT 2025 , Edited by admin on Wed Apr 02 05:44:52 GMT 2025
|
PRIMARY |